Efficacy and safety of pregabalin in neuropathic pain treatment: A still unreported adverse effect

Minerva Medica

Volumn 99, Issue 5, 2008, Pages 533-534

  Masa Vazquez L A ^a   Villamil Cajoto, I ^a   Villar Del Castillo, A ^a  

^a Hospital Gil Casares   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; PREGABALIN;

ADD ON THERAPY; ADULT; AGITATION; BRONCHOSPASM; CASE REPORT; CLINICAL PRACTICE; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; FEMALE; HUMAN; HYPESTHESIA; LETTER; NEUROPATHIC PAIN; RESPIRATORY FAILURE; SIDE EFFECT; SINGLE DRUG DOSE; TONGUE EDEMA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; ANALGESICS; BRONCHIAL SPASM; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPERESTHESIA; HYPESTHESIA; NEURALGIA;

EID: 57949112790     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Merskey H. Clarifying definition of neuropathic pain. Pain 2002;96:408-9.
2. Freynhagen R, Grond S, Schüpfer G, Hagebeuker A, Schmelz M, Ziegler D et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine Int J Clin Pract 2007;12:1989-96
3. Shneker BF, McAuley J. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacoter 2005;39:2029-37.
4. Lyrica. European Public Assessment Report. H-C-546 [internet]. [Last consultation 04/04/2008]. Available at: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/lyrica/084504en6.pdf